Here are three updates on GI companies from the past week:
The FDA granted Seres Therapeutics' SER-287 orphan drug designation. SER-287 treats pediatric ulcerative colitis.
The FDA approved Ferring Pharmaceutical's Clenpiq, a low-volume colonoscopy prep solution.
Takeda appointed Toshio Fujimoto, MD, to serve as the general manager of the Health Innovation Park in Shonan, Japan.